All In Biotech

Drug Trial Radar · NCT03776812

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase 2, Randomized, Open-Label, 3-arm Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Last checked: Nov 19, 2026Latest source record: Oct 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 178 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

178

Actual

Start

Apr 5, 2019

Primary completion

Mar 16, 2021

Study completion Jul 12, 2023

Sponsor

Lead sponsor
Corcept TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone.

Conditions

  • Recurrent Ovarian Cancer
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Primary Peritoneal Carcinoma

Interventions

  • RelacorilantDrug

    Relacorilant is supplied as capsules for oral dosing.

  • Nab-paclitaxelDrug

    Nab-paclitaxel is administered as IV infusion over 30-40 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Baseline and up to 15 months

Locations

24 sites in 5 countries. Site status is shown where the registry gives one.

  • Site Reference ID/Investigator #004

    Birmingham, Alabama

  • Site Reference ID/Investigator #038

    Scottsdale, Arizona

  • Site Reference ID/Investigator #032

    Denver, Colorado

  • Site Reference ID/Investigator #001

    Chicago, Illinois

  • Site Reference ID/Investigator #106

    Boston, Massachusetts

  • Site Reference ID/Investigator #128

    Boston, Massachusetts

  • Site Reference ID/Investigator #051

    New York, New York

  • Site Reference ID/Investigator #169

    New York, New York

  • Site Reference ID/Investigator #170

    New York, New York

  • Site Reference ID/Investigator #127

    Pittsburgh, Pennsylvania

  • Site Reference ID/Investigator #135

    Charlottesville, Virginia

  • Site Reference ID/Investigator #121

    Milwaukee, Wisconsin

  • Site Reference ID/Investigator #109

    Brussels, Belgium

  • Site Reference ID/Investigator #119

    Edegem, Belgium

  • Site Reference ID/Investigator #108

    Leuven, Belgium

  • Site Reference ID/Investigator #117

    Toronto, Ontario, Canada

  • Site Reference ID/Investigator #096

    Montreal, Quebec, Canada

  • Site Reference ID/Investigator #122

    Milan, Italy

  • Site Reference ID/Investigator #112

    Naples, Italy

  • Site Reference ID/Investigator #124

    Roma, Italy

  • Site Reference ID/Investigator #115

    Barcelona, Spain

  • Site Reference ID/Investigator #114

    Madrid, Spain

  • Site Reference ID/Investigator #116

    Madrid, Spain

  • Site Reference ID/Investigator #113

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.